Monitor Lucid Diagnostics' separate 8-K for full terms of the Series C Preferred, including conversion price and any anti-dilution provisions. The $15M injection reduces near-term cash burn risk for the subsidiary but creates future dilution overhang for PAVM common stock.
Price Chart
Executive Summary
PAVmed Inc. disclosed that its subsidiary, Lucid Diagnostics Inc., raised $15.0 million through the sale of 15,000 shares of newly designated Series C Convertible Preferred Stock at $1,000 per share to accredited investors. The offering closed on October 21, 2026, and Lucid Diagnostics also entered into a registration rights agreement for the resale of common stock issuable upon conversion. This capital infusion provides Lucid Diagnostics with growth funding but introduces potential dilution for PAVmed common shareholders through the conversion feature.
Key Financial Metrics
Key Facts
- Lucid Diagnostics, a PAVmed subsidiary, raised $15.0 million via Series C Convertible Preferred Stock.
- 15,000 shares of Series C Preferred Stock were sold at $1,000 per share.
- The offering closed on October 21, 2026.
- A registration rights agreement was executed for resale of common stock issuable upon conversion.
- The filing incorporates by reference Lucid Diagnostics' separate 8-K filed on October 22, 2026.
Financial Impact
$15.0 million gross proceeds to Lucid Diagnostics from the Series C Preferred Stock offering.
Risk Factors
- Potential dilution to PAVmed common shareholders upon conversion of Series C Preferred Stock.
- Lucid Diagnostics' ability to utilize the funds effectively to achieve milestones.
- Registration rights may lead to overhang from resale of converted common shares.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-048138 |
| Document: 0001493152-26-048138-index-headers.html | 0001493152-26-048138 |
| Document: 0001493152-26-048138-index.html | 0001493152-26-048138 |
| Document: 0001493152-26-048138.txt | 0001493152-26-048138 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | SC 13G/A | $2.26 | awaiting T+60 | — | $2.14 (−5.31%) |
Oct 22, 2026 5d ago | 8-K | $2.17 | awaiting T+60 | — | $2.14 (−1.38%) |
May 15, 2026 23w ago | 8-K | $6.53 $4.71 | ▲ +27.87% | ▲ +32.39% | $2.14 (+67.23%) |
Apr 20, 2026 27w ago | S-3 | $9.15 $6.02 | ▼ −34.17% | ▼ −41.07% | $2.14 (−76.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers